- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/01 - Virus à ADN
Détention brevets de la classe C07K 14/01
Brevets de cette classe: 296
Historique des publications depuis 10 ans
|
10
|
17
|
16
|
17
|
11
|
24
|
16
|
30
|
13
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Flagship Pioneering Innovations V, Inc. | 222 |
7 |
| Deutsches Krebsforschungszentrum | 419 |
6 |
| The University of North Carolina at Chapel Hill | 1990 |
6 |
| ContraFect Corporation | 79 |
5 |
| The General Hospital Corporation | 4642 |
4 |
| Kaneka Corporation | 4493 |
4 |
| Mitsui & Co., Ltd. | 62 |
4 |
| Proclara Biosciences, Inc. | 8 |
4 |
| Rakuno Gakuen University | 10 |
4 |
| Boehringer Ingelheim Vetmedica, Inc. | 123 |
3 |
| The Johns Hopkins University | 5524 |
3 |
| EpiVax, Inc. | 80 |
3 |
| NeuroPhage Pharmaceuticals, Inc. | 5 |
3 |
| Pherecydes Pharma | 18 |
3 |
| ProBioGen AG | 72 |
3 |
| The University of Tokyo | 4053 |
3 |
| The Wistar Institute of Anatomy and Biology | 436 |
3 |
| Othair Prothena Limited | 25 |
3 |
| The Regents of the University of California | 19493 |
2 |
| Genentech, Inc. | 3867 |
2 |
| Autres propriétaires | 221 |